{
    "clinical_study": {
        "@rank": "144543", 
        "arm_group": [
            {
                "arm_group_label": "Cohort 1", 
                "arm_group_type": "Experimental", 
                "description": "(N = 20 Moderately Impaired / Normal Hepatic Function) 100 mg GS-5816."
            }, 
            {
                "arm_group_label": "Cohort 2", 
                "arm_group_type": "Experimental", 
                "description": "(N = 20 Severely Impaired / Normal Hepatic Function) up to 100 mg GS-5816."
            }
        ], 
        "brief_summary": {
            "textblock": "This is a Phase 1 Open-Label, Parallel-Group, Single-Dose Study to evaluate the\n      Pharmacokinetics of GS-5816 in subjects with normal hepatic function and moderate or severe\n      hepatic impairment."
        }, 
        "brief_title": "A Phase 1 Study to Evaluate the Pharmacokinetics of GS-5816 in Subjects With Normal Hepatic Function and Moderate or Severe Hepatic Impairment", 
        "completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "condition": "Chronic Hepatitis C", 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis, Chronic", 
                "Hepatitis C", 
                "Hepatitis C, Chronic", 
                "Liver Diseases"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosis of chronic (> 6 months), hepatic impairment.\n\n          -  In the opinion of the Investigator, be in good health.\n\n        Exclusion Criteria:\n\n          -  Severe hepatic encephalopathy.\n\n          -  Prior placement of a portosystemic shunt.\n\n          -  Hepatorenal or hepatopulmonary syndrome.\n\n          -  Suspicion of hepatocellular carcinoma."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "33", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "March 20, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01817985", 
            "org_study_id": "GS-US-281-0112"
        }, 
        "intervention": {
            "arm_group_label": [
                "Cohort 1", 
                "Cohort 2"
            ], 
            "intervention_name": "GS-5816", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Hepatitis C (HCV) Infection", 
            "Moderate Hepatic Impairment", 
            "Severe Hepatic Impairment"
        ], 
        "lastchanged_date": "August 28, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Miami", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33014"
                    }, 
                    "name": "Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Miami", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33169"
                    }, 
                    "name": "Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Orlando", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32809"
                    }, 
                    "name": "Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Orlando", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32806"
                    }, 
                    "name": "Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Antonio", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "78215"
                    }, 
                    "name": "Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Juan", 
                        "country": "Puerto Rico", 
                        "zip": "00927"
                    }, 
                    "name": "Investigational Site"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Germany", 
                "Puerto Rico"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 1 Open-Label, Parallel-Group, Single-Dose Study to Evaluate the Pharmacokinetics of GS-5816 in Subjects With Normal Hepatic Function and Moderate or Severe Hepatic Impairment", 
        "overall_official": {
            "affiliation": "Gilead Sciences", 
            "last_name": "Diana Brainard, M.D.", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "The primary outcome measure is the pharmacokinetic parameters of GS-5816 which will include AUClast, AUCinf, and Cmax.", 
            "measure": "Pharmacokinetic parameters of GS-5816", 
            "safety_issue": "No", 
            "time_frame": "Up to one year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01817985"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "The secondary outcome measure is the number of incidences of adverse events and laboratory abnormalities.", 
            "measure": "Incidences of adverse events and laboratory abnormalities", 
            "safety_issue": "Yes", 
            "time_frame": "Up to one year"
        }, 
        "source": "Gilead Sciences", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Gilead Sciences", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}